Virax Biolabs to Present at 19th World Immune Regulation Meeting
Werte in diesem Artikel
LONDON, March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland.
Presentation Details:
Title:Evaluation of T cell dysfunction in post acute infection syndromes
Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs
Date: Wednesday, March 12, 2025, at 20:00
Location: Foyer A1, The Congress Center, Davos, Switzerland
Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
WIRM 2025 is an esteemed conference where approximately 600 scientists and clinicians from around the globe gather to discuss the latest advancements in immunology. This four-day event combines top-tier scientific lectures, informal networking, and a poster exhibition, all set against the stunning backdrop of Davos.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-present-at-19th-world-immune-regulation-meeting-302392440.html
SOURCE Virax Biolabs
Ausgewählte Hebelprodukte auf Virax Biolabs Group
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Virax Biolabs Group
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Virax Biolabs Group Aktie News
Virax Biolabs Group Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Virax Biolabs Group nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.

